UPS MD-11 Crash Prompts Families to Prepare Wrongful Death Lawsuit 
Sam Altman Reportedly Explored Funding for Rocket Venture in Potential Challenge to SpaceX 
Australia Moves Forward With Teen Social Media Ban as Platforms Begin Lockouts 
Germany’s Economic Recovery Slows as Trade Tensions and Rising Costs Weigh on Growth 
Novo Nordisk and Eli Lilly Lower Prices for Weight-Loss Drugs Amid U.S. Agreement 
OpenAI Moves to Acquire Neptune as It Expands AI Training Capabilities 
Trump Administration to Launch Autism Initiatives Targeting Acetaminophen Use and New Treatment Options 
Asian Currencies Steady as Markets Await Fed Rate Decision; Indian Rupee Hits New Record Low 
FDA Memo Raises Questions About Possible COVID-19 Vaccine Links to Rare Child Deaths 
Citi Sets Bullish 2026 Target for STOXX 600 as Fiscal Support and Monetary Easing Boost Outlook 
CDC Shake-Up Sparks Vaccine Policy Clash Between RFK Jr. and Susan Monarez 
Visa to Move European Headquarters to London’s Canary Wharf 
Australia’s Economic Growth Slows in Q3 Despite Strong Investment Activity 
Trump Signs Executive Order to Boost AI Research in Childhood Cancer 
Tesla Faces 19% Drop in UK Registrations as Competition Intensifies 
YouTube Agrees to Follow Australia’s New Under-16 Social Media Ban 
SK Bioscience has applied for conditional approval for the use of SKY Covione, a COVID-19 vaccine, with the European Medicines Agency (EMA).
SKY Covione, developed jointly by the biotech affiliate of SK Group and the Institute for Protein Design (IPD) at the University of Washington, is a synthetic vaccine considered safer than those originating from bacterial cultures.
The Bill & Melinda Gates Foundation provided funding for the product development.
According to Phase 3 clinical studies, the vaccine is significantly more immunogenic than the control vaccination Vaxzeria from AstraZeneca, according to SK Bioscience.
Extensive research in Phase 1 therapeutic trials showed that SKY Covione also induced a potent immune response against BA.1, of the Omicron variant family, when provided with booster shots.
The SK affiliate anticipates that the product will have a competitive advantage in the international market, which requires a consistent and stable supply of vaccines in the upcoming months.
Once it is added to the World Health Organization (WHO) Emergency Use List, it will be distributed to the global market through the COVID-19 Vaccines Global Access (COVAX) project, a global program created to enable equal access to COVID-19 vaccines.
According to data from the Korea Customs Service, Korea imported $2.35 billion worth of vaccines last year, a seven-fold rise from $340 million the year before.
